Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGC 101 - BioGenCell

Next Previous
Drug Profile

BGC 101 - BioGenCell

Alternative Names: BGC-101

Latest Information Update: 12 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioGenCell
  • Developer BioGenCell; Laniado Hospital
  • Class Haematopoietic stem cells therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peripheral arterial disorders; Peripheral vascular disorders

Most Recent Events

  • 09 May 2022 BioGenCell receives permission from the US FDA to continue phase II trial for BGC 101
  • 08 Jan 2020 BGC 101 is still in phase I/II trials for Peripheral arterial disorders and Peripheral vascular disorders in Israel (BioGenCell website, January 2020)
  • 11 Sep 2017 Interim efficacy and adverse events data from a phase I/II trial in Peripheral arterial disorders and Peripheral vascular disorders presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top